Additionally, advanced salvage options—such as repeat SRS and systemic therapies effective for intracranial and extracranial disease (e.g., melanoma and NSCLC with EGFR mutations or ALK translocations)—challenge the routine use of WBRT. Here, ALK is linked to non-small cell lung carcinoma.